Clinical Trial Update: Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical-trial update exploring adding ZEN003694 (ZEN-3694) and pembrolizumab to nab-paclitaxel for patients with locally advanced or metastatic triple-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer
• Unresectable Triple-negative Breast Cancer

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)
• Pembrolizumab (pembrolizumab)
• ZEN003694 (ZEN-3694) (ZEN-3694)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Status: RECRUITING